TY - JOUR
T1 - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Titer Levels in Pregnant Individuals after Infection, Vaccination, or Both
AU - Marshall, Christina L.
AU - Kaplowitz, Elianna
AU - Ibroci, Erona
AU - Chung, Kyle
AU - Gigase, Frederieke A.J.
AU - Lieber, Molly
AU - Graziani, Mara
AU - Ohrn, Sophie
AU - Lynch, Jezelle
AU - Castro, Juliana
AU - Tubassum, Rushna
AU - Mutawakil, Farida
AU - Jessel, Rebecca
AU - Molenaar, Nina
AU - Rommel, Anna Sophie
AU - Sperling, Rhoda S.
AU - Howell, Elizabeth A.
AU - Feldman, Hannah
AU - Krammer, Florian
AU - Stadlbauer, Daniel
AU - De Witte, Lotje D.
AU - Bergink, Veerle
AU - Stone, Joanne
AU - Janevic, Teresa
AU - Dolan, Siobhan M.
AU - Lieb, Whitney
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - We examined differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in pregnant individuals with natural, vaccine-induced, or combined immunity. Participants had live or nonlive births between 2020 and 2022, were seropositive (SARS-CoV-2 spike protein, anti-S), and had available mRNA vaccination and infection information (n=260). We compared titer levels among three immunity profiles: 1) natural immunity (n=191), 2) vaccine-induced immunity (n=37), and 3) combined immunity (ie, natural and vaccine-induced immunity; n=32). We applied linear regression to compare anti-S titers between the groups, controlling for age, race and ethnicity, and time between vaccination or infection (whichever came last) and sample collection. Anti-S titers were 57.3%and 94.4%lower among those with vaccine-induced and natural immunity, respectively, compared with those with combined immunity (P<.001, P=.005).
AB - We examined differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in pregnant individuals with natural, vaccine-induced, or combined immunity. Participants had live or nonlive births between 2020 and 2022, were seropositive (SARS-CoV-2 spike protein, anti-S), and had available mRNA vaccination and infection information (n=260). We compared titer levels among three immunity profiles: 1) natural immunity (n=191), 2) vaccine-induced immunity (n=37), and 3) combined immunity (ie, natural and vaccine-induced immunity; n=32). We applied linear regression to compare anti-S titers between the groups, controlling for age, race and ethnicity, and time between vaccination or infection (whichever came last) and sample collection. Anti-S titers were 57.3%and 94.4%lower among those with vaccine-induced and natural immunity, respectively, compared with those with combined immunity (P<.001, P=.005).
UR - https://www.scopus.com/pages/publications/85164572102
U2 - 10.1097/AOG.0000000000005172
DO - 10.1097/AOG.0000000000005172
M3 - Article
C2 - 37141599
AN - SCOPUS:85164572102
SN - 0029-7844
VL - 141
SP - 1199
EP - 1202
JO - Obstetrics and Gynecology
JF - Obstetrics and Gynecology
IS - 6
ER -